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CS14-04 The Development of an AIDS Mucosal Vaccine
Zhiwei Chen*. AIDS Institute, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Hong Kong SAR, China
Mucosal vaccination offers great advantage for inducing protec-
tive immune response at the sites of viral transmission. A novel
replication-competent modiﬁed vaccinia Tian Tan (MVTT) is an
attenuated variant of the wild-type VTT, which was historically
used as a smallpox vaccine for millions of people in China. MVTT
was generated through genetic engineering and clonal selection
of VTT and exhibited excellent safety proﬁles for mucosal inoc-
ulation. The spike glycoprotein (S) of SARS-CoV was used as a
test antigen after the S gene was constructed in the identical
genomic location of two live vectors to generate vaccine candi-
dates MVTT-S and MVA-S. A head-to-head comparison has been
conducted in mice for inducing neutralizing antibodies (Nabs)
via mucosal vaccination. Our results indicated that MVTT is su-
perior to MVA for inducing high levels of systemic Nab response
post mucosal vaccination. Moreover, a candidate vaccine MVTT-
SIVgpe, which expresses three major viral structural proteins of
simian immunodeﬁciency virus, has been recently characterized
in vitro. The efﬁcacy of MVTT-SIVgpe will be further evaluated in
a highly pathogenic SIV/Chinese macaque model.
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CS15-01 Can We Prevent Hepatocellular Carcinoma in
Chronic Hepatitis B?
Henry L.Y. Chan*. Department of Medicine and Therapeutics,
The Chinese University of Hong Kong
Hepatitis B virus (HBV) infection is the commonest cause of
hepatocellular carcinoma (HCC) most countries in Asia. After the
launching of the universal vaccination program, the incidence
of childhood HCC has been dramatically reduced in Taiwan. As
HCC in adult commonly develop at the age the 40 to 50 years, it
may take another 20 to 30 years before one can see a signiﬁcant
reduction in incidence of adult HCC.
Clearance of HBsAg is the marker of ultimate viral control in
chronic hepatitis B. If HBsAg clearance occurs before the age
of 50, the prognosis is excellent. However, spontaneous HBsAg
clearance is rare. Peginterferon and oral antiviral agents can
induce HBsAg clearance in about 10% and 5% of patients, respec-
tively. High HBV DNA has been found to associate with higher risk
of HCC. However the data from individual studies on the long
term beneﬁt of interferon or antiviral agent is conﬂicting.
A meta-analysis has been conducted to investigate the beneﬁcial
effect of interferon and antiviral agents (mainly lamivudine) on
HCC. Interferon is associated with an approximate 33% reduction
in risk of HCC. Lamivudine is associated with an approximate 80%
reduction in risk of HCC.
In summary, vaccination can prevent HCC by preventing HBV
infection. HBsAg clearance in an early age can almost prevent
HCC. Interferon and antiviral treatment can reduce the risk but
not completely prevent HCC.
CS15-02 Current Japanese Strategies for Preventing HCC
Development
Yoshiyuki Ueno*. Division of Gastroenterology, Tohoku
University Graduate School of Medicine, Sendai, Japan
In Japan, the death caused by liver disease is still major problems
in health care. Most importantly, the death from liver diseases
exceeds 30,000 cases in Japan. Approximately, nearly 80% of
these death is derived from hepatitis C virus (HCV) related liver
diseases, namely hepatocellular carcinoma (HCC).
Although the incident of HCV infections is decreasing in Japan
due to current screening strategies, the patients with estab-
lished infections have reached their most susceptible stage for
developing HCC. In other words, the Japanese patients with
HCV infection are facing highest risk for developing HCC. The
current preventive strategies for developing HCC includes anti-
viral therapy, namely interferon based regimen. However, the
results of current standard therapy, PEG-interferon plus ribavirin
treatment, is not satisfactory in genotype 1b with high viral
load, which is most commonly observed population in Japan
and US. The recent reports have documented up to 50% of the
patients treated with antiviral therapy eradicated HCV genotype
1b infection. Moreover, the adherence to the antiviral therapy
is poorly tolerated in elderly populations, which is now biggest
patients’ population in Japan. Thus, in Japanese society, the
eradication of HCV itself seems more and more difﬁcult. More-
over, the social beneﬁt regarding antiviral treatment in elderly
patients, especially above 70 years old, has not been established.
The patients in this age have the highest risk for developing HCC
and poorest results after antiviral treatment. Furthermore, these
patients tend to be intolerant to the interferon based treatment.
Adverse effects such as depression are more commonly observed
in these elderly patients. Besides these anti-viral treatments,
so-called maintenance therapies are frequently applied to these
elderly populations. Low-dose interferon monotherapy, oral in-
take of ursodeoxy cholic acids, and phlebotomy are included in
these maintenance therapies. However, the recent results from
HALT-C gave questions about the rational of long-term interferon
monotherapy. Thus, the evidences for preventing HCCs by these
maintenance therapies seem to be weak.
In summary, the Japanese strategies for preventing HCC devel-
opment is; i) eradicate the possible as early as possible since
the adherence to the standard antiviral treatment is poor in
elderly patients with HCV, ii) perform social education for un-
derstanding the natural course of HCV infection to accept the
early eradicative treatment, iii) establish the social supportive
program to receive antiviral therapy (both medical and econom-
ical), and iv) develop interferon free based antiviral treatment
to increase the adherence of antiviral therapy in elderly popula-
tions.
CS15-03 Prevention of HCC Related to Viral Hepatitis
Jun Cheng*. Beijing Ditan Hospital, Beijing, China
CS15-04 The Role of Polo-like Kinase 1 as a Therapeutic
Target in Hepatocellular Carcinoma
Seng-Gee Lim*. National University Health System, Singapore
Polo-like kinase 1 (PLK1) plays important roles in the progres-
sion of cell cycle, especially for cells transiting from anaphase
to telophase during mitosis. PLK1 has been found to be over-
expressed in various cancers, and has important prognostic im-
plications.
Methods: PLK1 gene expression was evaluated in Hepatocellular
carcinoma (HCC) and found to be overexpressed frequently in
HCC tissues. Gene silencing technology utilizing short interfering
RNA (siRNA) was subsequently employed to study the potential
of PLK1 to be the therapeutic target in treating HCC. Knockdown
with si-RNA was performed to examine for reduction in cell
proliferation using MTS and BrdU assays, after validating reduced
expression by real-time PCR (RTPCR) and Western Blotting. Con-
ﬁrmation of apoptosis was performed using TUNEL assay, and
subsequent pathway of apoptosis was examined using a caspase-
inhibition assay. Experiments with transplanted tumour cell lines
into nude mice co-cultured with si-RNA against the target gene,
and examining for reduced tumour progression compared to
controls was performed.
Results: Microarray analysis showed the most common over-
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expressed gene was PLK1 by 12 times, and was also found to be
over-expressed in Huh-7 cells. SiRNA against PLK-1 validated by
real-time PCR (RTPCR) and Western Blotting showed a reduction
of PLKR1 expression up to 96% in huh-7 cells, and reduced cell
proliferation by 68% and 92% in MTS and BrdU cell proliferation as-
says respectively. There was 3-fold increase in apoptosis events,
and TUNEL staining and caspase-3 assays suggested that this may
be caspase-independent. The pan-caspase inhibitor Z-VAD-FMK
was unable to rescue apoptotic cells. Immnoﬂuorescence studies
co-localised endonuclease G to fragmented chromosomes, thus
was postulated to be the main apoptotic effector. Knockdown
of the FOXM1 transcription factor, thought to be a positive reg-
ulating factor did not affect PLK1 gene expression, suggesting
other transcription factors may be important. Finally, huh-7 cells
transplanted subcutaneously into nude mice using matrigel were
treated with si-PLK1 and control si-RNA. Tumour regression of
33% occurred in the mice treated with si-PLK1 but not in controls.
Conclusion: PLK1 overexpression in HCC was shown to be func-
tionally important by gene silencing experiments, and may be a
potential therapeutic target.
Concurrent Session 16 – Global Monster – MRSA
CS16-01 A Work in Progress: MRSA and cMRSA in Latin
America
Raul E. Isturiz *. Department of Medicine, Infectious Diseases,
Centro Medico de Caracas, Caracas, Venezuela
MRSA is the leading cause of nosocomial infection in Latin Amer-
ica, and the number of reports of community-acquired (cMRSA)
infections continue to rise.
The full extent of the problem is unknown because surveillance
information is only available from large hospitals, while much
of the population is cared for in small centers that do not per-
form microbiological testing or use different methodology and
deﬁnitions. Under these conditions, monitoring the epidemiology
of MRSA remains a challenge and there is a need to improve
detection and management.
Nosocomial, multidrug-resistant MRSA is a growing problem in
Latin America with estimated prevalence for the region currently
near or above 50% for non blood stream infections and over 40%
for bacteremia.
Reports of CA-MRSA infections initially came from Brazil in 2003.
Soon, a large outbreak of CA-MRSA infection that affected in-
mates in jails and people from the community in Uruguay was
described; more than 1000 patients were affected and 12 died.
In the region SSTIs account for the majority of cases, but severe
forms of pneumonia were reported, including 4 deaths. In this
outbreak, TMP-SMX remains active in vitro and is used for the
treatment of skin infections.
Interestingly, an apparent decrease in MRSA strains with van-
comycin MIC greater or equal to 1 μg/ml suggests a shift in clonal
dissemination, and further data are required to follow this trend,
which may have important implications for treatment.
Although surveillance systems in Latin America are improving,
many limitations remain.
CS16-02 Elucidating Geographical Spread of Methicillin-
Resistant Staphylococcus aureus (MRSA): From
Molecular Typing, Multilocus Sequence Typing to
Microbial Genomics
Margaret Ip*. Dept of Microbiology, Chinese University of Hong
Kong, Prince of Wales Hospital, Shatin, Hong Kong
Methicillin-resistant Staphylococcus aureus (MRSA) is a leading
cause of hospital-acquired infections and an increasingly recog-
nized pathogen from the community worldwide. MRSA infections
are associated with high morbidity and mortality, and are a major
ﬁnancial burden to healthcare globally.
A number of typing methods, including pulsed-ﬁeld gel elec-
trophoresis (PFGE), has been used by international surveillance
networks to study the relationships and spread of MRSA iso-
lates geographically. It was established that the large majority
of MRSA isolates belong to a limited set of epidemic clones
worldwide, namely the Brazilian, Iberian, New York/Japan, Pae-
diatric clones. Methicillin resistance is conferred by the penicillin
binding protein PBP2’, encoded by the mecA gene, present in
a large fragment of mobile DNA designated “staphylococcal
cassette chromosome”, SCCmec. More recently, sequence-based
methods have been employed in the analyses of these isolates.
Multilocus sequence typing (MLST) requires the sequence de-
termination of internal fragments of 7 housekeeping genes for
each strain. Each identical sequence is assigned an allele num-
ber, and the combination of alleles at each locus deﬁnes its
sequence type (ST). The combination of MLST and SCCmec typing
applied on international collections of MRSA revealed that these
epidemic MRSA clones emerged on repeated acquisition (over
20 times) of SCCmec by successful methicillin-susceptible S.
aureus (MSSA) clones belonging to ﬁve phylogenetically distinct
lineages or clonal complexes (CCs): CC8, CC5, CC45, CC22 and
CC30.
MRSA is endemic in Hong Kong hospitals. Our previous study
on MRSA causing bacteremia in Hong Kong hospitals belonged
to four clonal complexes CC5, CC45, CC49 and CC239. The
most prevalent MRSA clone in Hong Kong belonged to CC239,
with PFGE types A-E, and H, SCCmec type III, and belonged to
sequence type, ST239, with a multidrug resistance proﬁle to
tetracycline (T), erythromycin (E), clindamycin (D), gentamicin
(G), tobramycin (To) and ciproﬂoxacin (Ci). Evidence also sup-
ports the prevalence of CC239 in Asian countries including China,
Singapore, Taiwan, and Indonesia, whereas MRSA strains from
Korea and Japan belonged to CC5 that had SCCmec type II.
With advances in sequencing technology, the evolutionary history
of the MRSA clone ST5 was further studied by mutation discovery
at 108 loci (46kb) within a global collection. Sequence polymor-
phisms in 1.6% (46,483 bp) of the genome from each MRSA strain
was screened. The SNPS deﬁned a radial phylogenetic structure
within ST5 consisting of at least 5 chains of mutational steps that
deﬁne geographically associated clades. Mapping of the indepen-
dent imports of the SCCmec demonstrated import occurred at
least 23 occasions, and that the progeny of such recombinant
strains are locally rather than globally. This further exempliﬁes
that geographical spread of MRSA over long distances and across
cultural borders is a rare event compared with the frequency
with which SCCmec has been imported.
CS16-03 Molecular Characteristic of
Community-Acquired, Methicillin-Resistant
Staphylococcus aureus
Xuzhuang Shen*. Education Department, Beijing Children’s
Hospital Afﬁliated to Capital Medical University, Beijing, China
MRSA became the most common nosocomial pathogen in many
hospitals since the 1980s, especially in many Asian countries. Epi-
demiologic reports showed that >50% of S. aureus isolates from
the hospitals in Korea, Japan, Taiwan, Hong Kong, Singapore,
and Sri Lanka were MRSA. MRSA infection is now increasingly
reported in the community. According to the ANSORP study from
2004 to 2006 in 9 Asian countries, the prevalence of MRSA among
community-associated S. aureus isolates was 20.8% in Asian re-
gion and it was the highest in Taiwan (40.5%), followed by Sri
Lanka (38.8%), the Philippines (30.1%), and Vietnam (28.2%).
Skin and soft tissue infection was the most common infection by
community-associated MRSA (CA-MRSA) followed by respiratory
tract infection and primary bacteremia. CA-MRSA isolates from
Asian region showed diverse microbiologic and genetic features
